Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of PRAX-114 for adjunctive treatment of MDD

Next Previous
X
Search
Trial Profile

A Phase 2 Study of PRAX-114 for adjunctive treatment of MDD

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 15 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRAX-114 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 15 May 2021 New trial record
    • 11 May 2021 According to a Praxis Precision Medicines media release, the company plans to initiate this study in the third quarter of 2021. Topline results are expected in the first half of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top